Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig dose-ranging placebo-controlled study in adults with moderate-to-severe asthma
jRCT2031230533Completed
- Sponsor
- Sanofi
- Start
- Feb 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of lunsekimig in asthma (5 arms), sponsored by Sanofi. Primary endpoint: Annualized rate of asthma exacerbation events. Started Feb 2024; status: completed.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031230533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230533.